Good find. Unfortunately, the science of immunotherapy and its milestones eludes me. Maybe someone can flesh it out. Whatever the case, it's a positive development.

69M shares in the float post 1:1 dividend. Effect on pps should be minimal. If company delivers on its goals, pps should be relatively stable.